With cannabis flower the first-choice for many patients with chronic pain, one company tells Cannabis Health about its aim to make inhalation a medically approved method of consumption.
An increasing number of countries are beginning to permit the use of cannabis for medicinal purposes. The most popular and, arguably, more effective method of administration is smoking, but due to the associate health risks, medical professionals are reluctant to prescribe cannabis flower.
Medicinal cannabis is generally prescribed as an oil or tincture, allowing doctors to give an accurate prescription. However, the majority of people who use cannabis to treat a chronic health issue, such as acute pain, choose to consume the plant via inhalation (such as smoking or vaping).
Patients claim that it is more effective for treating their symptoms and although the number of studies to back this up are limited, there is a growing body of research looking at the effects of smoking cannabis flower on pain relief.
A recent study from the University of New Mexico, for example, found that patients suffering with pain were able to better manage their condition by smoking flower, rather than other administration methods.
Described as a ‘silent epidemic’ by the British Pain Society, chronic pain is thought to affect between one third and one half of the UK population.
Due to the side effects associated with stronger pharmaceutical painkillers, many people are turning to cannabis to treat their pain. Some people use CBD, whilst others require the THC content found in cannabis flower.
The study also revealed that THC was essential for effectively treating pain and suggests that moderate to high levels of the cannabinoid is an “effective mid-level analgesic”.
Given its high bioavailability and quick onset compared to oral consumption, smoking cannabis flower for pain appears to be a natural choice for many.
Kanabo, an Israeli company producing cannabis vapes, is aiming to “medicalise vaporisation” and convince health professionals that inhalation can be a medical route of administration.
Recognising the fact that most medical cannabis consumers favour smoking flower over consuming cannabis oils and tinctures, the company has developed a vaping device that can provide a consistent dose of cannabis, whilst also providing the benefits of inhaling the medicine.
One of the main barriers to making inhalation a medically recognised administration method is the inconsistency of smoking, not to mention the associated risks to patients’ health.
It is understandable that most doctors prescribing cannabis-based medical products favour oils, tinctures and tablets over cannabis flower. In general, doctors feel comfortable prescribing medicines that can be administered orally, despite many patients reporting that ingesting cannabis does not provide the desired effects.
Kanabo’s CEO and founder, Avihu Tamir told Cannabis Health: “The number one thing physicians are saying is that they feel uncomfortable prescribing flower. Not because they don’t believe in the health benefits and the potential of this plant, most doctors supporting cannabis do.
“It is because they don’t see it as is a medicine, they say it’s an agricultural plant. It’s not something that you can prescribe a specific dose of, it’s not something that is consistent.”
Tamir continued: “We’re trying to come in between and make everyone happy. Vaporisers, at the end of the day, are mimicking all of the benefits you have when you smoke; the fast onset and the high bioavailability. But at the same time you don’t have the tar in your lungs and you have the metered dosing.”
Although it is easier to prescribe a measured dose of cannabis in oil or tablet form, oral consumption can be unpredictable and the effects often last longer than desired.
When inhaled, the effects can reduce to lower levels within just a few hours, however when ingested, it can take as long as eight hours or more.
Kanabo says its device, the VapePod, can accurately provide the same dose of cannabis on each inhale, allowing doctors to provide accurate prescriptions whist also giving patients their preferred administration method.
“In the cartridge, you’re getting the same consistency of formula – the same levels of CBD levels and THC and even the same levels of terpenes,” Tamir said.
“You have the capability to suddenly prescribe because it’s measurable; you can say every inhalation is one milligram for example.
“It means doctors can speak the language that they’re used to. They have something that is very consistent, which is similar to the benefit they have with oils. And on top of that, it’s a medical device with a medical certification for the formula.”
Through clinical trials currently taking place in Israel, Kanabo hopes to build the data surrounding vaping which is less abundant compared to data on smoking and cannabis oil.
“We’ll be able to see the bioavailability graphs for a vape pen, so for the first time, patients and physicians will see how it looks as a graph of bioavailability,” Tamir added.
“We know today how oils are working. We know today how smoking is working, but it will be the first time that people will see this bioavailability graphs of extract-based vape.”
Ireland to fund patient’s medical cannabis up front
Campaigner Vera Twomey described “relief” that her determination has finally paid off.
Campaigner Vera Twomey has described her “relief” as the Irish Government agrees to fund medical cannabis patient’s prescriptions up front.
Eligible medical cannabis patients in Ireland will now have their medication paid for up front, after months of pressure on the Government from campaigners.
Health Minister Stephen Donnelly announced on Monday 19 July that the refund system for patients who obtain their prescribed cannabis-based products from the Netherlands, will now be replaced by a direct payment system.
The HSE will pay the dispensing pharmacy in the Netherlands directly, rather than the burden falling to the patients and their families, who were then required to apply for a refund.
Vera Twomey, whose daughter Ava Barry, 11, has a severe form of epilepsy known as Dravet syndrome, is among 40 patients who have now been granted an individual ministerial licence to import Bedrocan oil to Ireland.
But the family were paying 10,000 Euros up front every three months for Ava’s prescription and waiting up to five weeks for it to be refunded.
Twomey, who has four other children, has previously spoken of the huge financial strain this system placed on her family.
Over the last 16 months she has relentlessly called for action, making dozens of phone calls daily to politicians and lobbying ministers on social media with the backing of thousands of supporters in Ireland and across the world.
Twomey, who received a phone call from Ireland’s Prime Minister, Micheál Martin on Monday confirming the news, says she is “delighted” that her determination has finally paid off.
“There’s a sense of relief that we have accomplished this, but also a little bit of shock because we have been trying to resolve it for so long,” she told Cannabis Health.
Twomey’s activism gained national attention in 2017 when she walked from her home in Cork to Leinster House in Dublin to ask former Health Minister Simon Harris to grant access to medical cannabis for her daughter.
Initially having to travel to the Netherlands to collect the prescription herself, during the pandemic Twomey successfully campaigned to secure the permanent delivery of Bedrocan oils for Ava and other patients.
Now she says she is looking forward to focusing on her family and putting the phone down for a while.
“I don’t think anybody who has gone through this fight, seeing the injustice that we have had to deal with could ever walk away,” she said.
“But at the same time, I’ve made a lot of sacrifices and for the moment at least, I need to give 100 percent to my other children, to do normal things and be a family.”
But the fight in Ireland isn’t over.
The Irish Government announced the provision of funding for the Medical Cannabis Access Programme (MCAP) in January – almost two years after it was introduced – but only four low dose cannabis-based medicines are covered by the programme, for people living with one of three qualifying conditions.
“There are other issues – we still need expansion and improvement in medical cannabis access, the journey is over by any means, but we’re at the beginning and getting Bedrocan recognised as a medicine that is funded up front is very important.
“I think the Irish are actually miles ahead of the British on this one and I hope [politicians] will take notice and catch up.”
She added: “The greatest gift you’ll ever receive is to lose your fear, then you can accomplish anything with focus and determination.
“If you have the determination to keep going you will get there. It’s not going to be easy, they are not going to make it easy but it can be done.”
Patients eligible for the direct payment system are those suffering from one of three stated conditions; spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy and severe, refractory (treatment-resistant) epilepsy.
The HSE says it will be contacting patients directly.
Health Minister, Mr Donnelly, commented: “I am delighted that the HSE and Transvaal Apotheek in the Netherlands are implementing a new process which will give peace of mind to the seventeen patients and their families who until now have been using the refund process.”
Kanabo’s cannabis vaporiser for metered dosing launches in UK
The VapePod will give thousands of UK patients access to pain relief in a metered dose.
Cannabis company Kanabo’s new extract formula and vaporiser will give thousands of UK patients access to pain relief in a metered dose.
UK patients will be the first in Europe to have access to Kanabo’s vaporiser, the VapePod, and its new extract formula when is it delivered later this month.
The deal, in conjunction with LYPHE Group, will see patient’s of LYPHE Group’s ecosystem, including The Medical Cannabis Clinic and Dispensary Green, able to access the VapePod under the brand name NOIDECS.
Under the agreement, PharmaCann and Kanabo established a customised production line for Kanabo’s VapePods cartridges.
An alternative to cannabis flower
The VapePod is a medical-grade, handheld vaporiser which enables accurate and precise micro doses of cannabis extract, dispensing 1mg of formula for each inhalation.
This will benefit to patients as inhaling extracts rather than tinctures and oils allows for faster onset and higher bioavailability.
It will also allow clinicians to more confidently prescribe and monitor a patient’s dosage, as well as providing more accurate patient data.
Previously, cannabis patients in the UK have only been able to access medical cannabis dry flower and oil tinctures for which the majority of patients consume via inhalation due to fast onset time.
Kanabo’s medical line aims to enable patients to move away from the harmful act of smoking medical cannabis flowers as they can now take their medicine without inhaling soot, tar and carcinogens into the lungs.
Avihu Tamir, Kanabo’s CEO, said: “The VapePod is a world first allowing specialist consultants to prescribe a metered dose of medicinal cannabis that is healthier for patients than the alternative, which is typically smoking.
“Medical cannabis is a safer alternative to the conventional opiate solutions and other pain management treatments. This announcement ensures that thousands of UK patients have access to the most effective medicinal cannabis delivery system.
“The fact that the VapePod gives exactly 1mg on every inhalation is crucial for GPs because they can prescribe an exact dose which they haven’t been able to do before. For patients who want the similarity to smoking but know they are not inhaling soot and tar. There’s also the bioavailability factor too.
“The reason GPs haven’t been prescribing is the issue of dosing and flowers – they don’t feel comfortable asking patients to smoke. With Kanabo, they can prescribe exact dosing in a safe and consistent way.”
The medical extract formula, which is based on the Israeli medical cannabis pharmacopoeia as a recommendation for the treatment of pain management, has a purity of 70 percent THC with 15 percent minor cannabinoids and terpenes.
Earlier this year Kanabo became the second cannabis company to list on the London Stock Exchange.
Dean Friday, LYPHE’s CEO commented: “Kanabo are experts in novel delivery with their VapePod greatly improving onset times, and for our chronic pain patients we now have an alternative to flower vaporisation. This is the start of a revolution in medical cannabis application and we are delighted to be supplying it under the NOIDECS brand.”
Cancer survivors turn to cannabis for physical and mental health – study
Cancer survivors are more likely to use cannabis to help pain, anxiety, sleep and nausea.
Cancer survivors are frequently using cannabis to manage physical and mental health symptoms, says a new study.
Research from the US indicates that cancer survivors are more likely to use cannabis for symptoms such as pain, anxiety, trouble sleeping and nausea.
A team of investigators analysed results from a Covid-19 cannabis health study to examine changes to cannabis use, methods of cannabis delivery, and coping strategies among cancer survivors since the pandemic.
They found that individuals with a history of cancer are more likely to report cannabis use to manage mental health and pain symptoms.
This group of people were also more likely to report fear of a Covid-19 diagnosis, compared to adults without a history of cancer.
Data was collected from 158 responses between 21 March 2020 and 23 March 2021, from cancer survivors who identified as medicinal cannabis users.
These were then compared to medicinal cannabis users without a history of cancer of the same age.
According to the study, cancer survivors were more likely to report using cannabis as a way of managing nausea/vomiting, headaches or migraines, seizures, sleep problems or as an appetite stimulant.
Sixty one percent of respondents with a history of cancer used cannabis to manage anxiety symptoms and 54 percent for chronic pain.
Forty eight percent said they used it to manage depressive symptoms and 25 percent for PTSD, while smaller numbers used it for symptoms of another autoimmune disease, and irritable bowel syndrome.
While there were no differences in how often they used cannabis or their method of administration, cancer survivors were “more likely to have an advanced supply of cannabis”.
The findings support the need for more conversations between doctors and their patients about the use of cannabis, say those behind the study.
The authors concluded: “Overall, we observed that cancer survivors are frequently reporting the use of cannabis to manage both physical and mental health symptoms associated with their cancer diagnosis and that cancer survivors are more likely to report fear of a Covid-19 diagnosis compared to those without a history of cancer.
“Given the frequency of mental and physical health symptoms reported among cancer survivors during the Covid-19 pandemic period, clinician–patient interactions should include questions around cannabis use, particularly those with a history of cancer.”
Introducing our new B2B title
- Cystic fibrosis and cannabis – new survey highlights lack of education
- Why are cannabis medicines helpful for fibromyalgia?
- Alzheimer’s disease: Could cannabis be an effective treatment?
- Five ways to practice mindfulness with CBD
- Medical cannabis cultivation gets green light in Guernsey
- Cannabis and motherhood: “My children get to see me smile more”
News1 year ago
NHS lines up cannabis medicine manufacturing
News8 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies1 year ago
CBD oil and fibromyalgia – a case study
News10 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Insight10 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
Feature1 year ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
News7 months ago
UK grants second licence to grow high-THC medical cannabis
Industry6 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month